AWM Capital LLC Sells 268 Shares of Johnson & Johnson (NYSE:JNJ)

AWM Capital LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 9.4% in the 4th quarter, HoldingsChannel reports. The firm owned 2,575 shares of the company’s stock after selling 268 shares during the period. AWM Capital LLC’s holdings in Johnson & Johnson were worth $404,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Dock Street Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 25.9% during the 3rd quarter. Dock Street Asset Management Inc. now owns 3,276 shares of the company’s stock valued at $510,000 after purchasing an additional 674 shares during the last quarter. Perfromance Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 1.3% during the third quarter. Perfromance Wealth Partners LLC now owns 53,086 shares of the company’s stock valued at $8,268,000 after buying an additional 660 shares during the last quarter. SC&H Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 5.1% in the third quarter. SC&H Financial Advisors Inc. now owns 2,149 shares of the company’s stock worth $335,000 after buying an additional 105 shares during the period. Choate Investment Advisors boosted its holdings in Johnson & Johnson by 13.6% during the 3rd quarter. Choate Investment Advisors now owns 90,366 shares of the company’s stock valued at $14,075,000 after acquiring an additional 10,822 shares during the period. Finally, Strengthening Families & Communities LLC increased its stake in Johnson & Johnson by 6.9% in the 3rd quarter. Strengthening Families & Communities LLC now owns 15,243 shares of the company’s stock worth $2,374,000 after purchasing an additional 981 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $152.12 on Thursday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The stock has a 50-day moving average price of $151.73 and a 200-day moving average price of $155.11. The firm has a market cap of $366.10 billion, a PE ratio of 9.57, a P/E/G ratio of 2.51 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.68 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Morgan Stanley cut their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Check Out Our Latest Analysis on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.